1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Anhui Fengyuan Pharmaceutical Co., Ltd Class A

Anhui Fengyuan Pharmaceutical Co., Ltd Class A

SSZSE:000153
5.59
CNY
+0.03
(+0.54%)
0.22EPS
21.68P/E
2.36BMarket Cap
Anhui Fengyuan Pharmaceutical Co., Ltd Class A
SZSE:000153
(Shenzhen Stock Exchange)

Recent

price

5.59

P/E

ratio

21.68

div

yld

4.83%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
2.95
4.18
4.55
3.65
3.89
3.59
4.65
5.89
6.79
7.4
7.6
8.36
9.02
9.2
9.22
8.3
7.51
Revenue per Share
0.11
0.03
0.05
0.07
0.09
0.08
0.1
0.15
0.14
0.18
0.24
0.28
0.35
0.34
0.35
0.21
0.23
Basic EPS, GAAP
-0.1
-0.04
-0.14
-0.44
-0.38
0.02
0.13
0.01
0.34
-0.18
0.23
0.24
0.81
0.22
-0.04
-0.22
- -
Free Cash Flow per Basic Share
0.04
0.04
0.06
0.12
0.07
0.07
0.14
0.08
0.07
0.12
0.09
0.06
0.13
0.14
0.16
0.17
0.27
Dividend per Share
1.96
1.98
2.02
2.47
2.55
2.67
2.64
2.75
2.9
3.03
3.23
3.99
3.72
4.06
4.35
4.53
4.65
Book Value per Share
1.52
1.5
1.52
2.05
2.12
2.24
2.29
2.42
2.5
2.61
2.73
3.45
3.17
3.43
3.69
3.85
3.97
Tangible Book Value per Share
364
364
364
419
437
437
437
438
444
438
437
437
444
465
465
465
465
Basic Weighted Avg Shares
1,074
1,521
1,658
1,530
1,699
1,569
2,034
2,578
3,013
3,238
3,321
3,652
4,004
4,275
4,285
3,858
3,491
Sales/Revenue/Turnover
3.98
1.37
2.24
3.35
3.87
4.1
4.52
5.16
4.61
4.86
4.85
5.52
5.8
5.66
5.76
4.83
5.6
Operating Margin (%)
50
51
52
59
69
64
69
75
75
71
71
115
122
126
128
148
- -
Depreciation Expense
42
11
19
27
41
35
46
65
61
81
104
123
154
159
161
99
109
Net Income, GAAP
23.01
26.02
28.45
33.93
27.09
25.31
31.32
32.41
34.79
32.79
26.08
26.26
25.38
26.8
24.47
24.27
19.73
Effective Tax Rate (%)
3.88
0.72
1.15
1.79
2.41
2.24
2.25
2.53
2.02
2.5
3.12
3.37
3.86
3.73
3.75
2.58
3.11
Profit Margin (%)
68
9
10
266
9
-26
-71
6
-52
-296
-363
-70
-267
-111
-223
-280
-381
Working Capital
40
- -
60
197
68
59
43
- -
- -
105
65
115
190
195
213
300
215
LT Debt
754
764
775
1,120
1,147
1,199
1,153
1,220
1,292
1,327
1,448
1,771
1,755
1,919
2,046
2,126
2,184
Total Equity
3.12
0.64
0.99
1.4
2.06
1.48
-0.36
3.7
3.51
4.6
4.71
5.04
6.01
5.97
5.45
3.05
2.96
Return on Invested Capital (%)
5.43
2.25
3.25
3.11
3.93
3.49
3.76
5.05
4.8
5.92
6.65
6.93
7.39
7.23
6.63
4.19
4.07
Return on Capital (%)
6.01
1.53
2.61
3.02
3.74
3.09
3.95
5.51
4.86
6.19
7.58
7.8
8.9
8.81
8.23
4.82
5.14
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
787
874
1,297
LT Borrowings
287
272
204
LT Finance Leases
13
11
11
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
465
465
465
Market Capitalization
2,914
3,048
2,356

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,096
2,348
2,089
Cash, Cash Equivalents & STI
387
471
480
Accounts Receivable, Net
990
1,056
943
Inventories
544
592
518
Total Current Liabilities
2,376
2,616
2,470
Payables & Accruals
- -
- -
- -
ST Debt
787
874
1,297
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.1%
8.25%
3.91%
Free Cash Flow
377.13%
105.14%
469.76%
Net Income, GAAP
13.71%
2.01%
-38.19%
Sales/Revenue/Turnover
9.99%
3.33%
-9.95%
Total Cash Common Dividend
20.31%
24.75%
12.46%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,121
1,187
954
1,023
4,285
2025
941
1,086
- -
733
3,858
2026
836
835
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.1
0.11
0.1
0.03
0.35
2025
0.08
0.08
- -
- -
0.21
2026
0.08
0.07
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.12
0.01
0.01
0.16
2025
0.02
0.12
- -
0.02
0.17
2026
0.02
0.12
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Anhui Fengyuan Pharmaceutical Co., Ltd. (000153.SZ) researches, develops, produces, and sells a broad range of pharmaceutical products primarily in China, with exports to Africa, Southeast Asia, Central Asia, Europe, and other international markets. The company offers biopharmaceuticals, chemical pharmaceuticals, Chinese patent medicines, Chinese herbal decoction pieces, and active pharmaceutical ingredients (APIs), spanning categories such as gynecology, respiratory system, hormonal, antipyretic analgesic, mental health, antiviral, antibiotic, oral anesthetic, masks, urinary, water electrolyte balance, digestive system, cardiovascular, Yinpian, and nutrition and metabolism; key products include peritoneal dialysis solutions, electrolyte series, fructose series, fatty milk emulsions, amino acid series, ambroxol hydrochloride injections, isosorbide mononitrate injections, levofloxacin lactate injections, ibutilide fumarate injections, cilnidipine tablets, dexamethasone phosphate injections, oxytocin injections, and diclofenac sodium patches. Founded in 1997 and headquartered at No. 16 Dalian Road, Baohe Industrial Park, Hefei, Anhui Province, China, it operates as a high-tech enterprise and the first listed pharmaceutical company in Anhui Province, integrating R&D, manufacturing, and commercial distribution across multiple dosage forms and over 300 varieties. In recent developments, the company reported operating revenue growth in its Q3 2025 financials, with a strategic focus for 2025 on expanding core high-margin varieties, enhancing refined management for cost efficiency, accelerating new drug development, and increasing classic traditional Chinese medicine formulas to enrich its pipeline amid low current TCM revenue contribution of less than 1%. It continues to prioritize biopharmaceuticals, chemical drugs, and traditional Chinese medicines while pursuing operational efficiencies and product diversification.